The US FDA Grants Orphan Drug Designation to Candel Therapeutics’ CAN-2409 as a Treatment for Pancreatic Cancer
Shots:
- The company’s CAN-2409 has received the US FDA’s orphan drug designation based on its ongoing P-II clinical evaluation in combination with valacyclovir and SoC chemoradiation as a treatment for borderline resectable pancreatic cancer
- The study, as of Mar 2024, demonstrated an improved mOS of 28.8mos. with CAN-2409 vs 12.5mos. in the control arm, a survival rate of 71.4% vs 16.7% was observed in patients post chemoradiation at 24mos. and an estimated survival of 47.6% vs 16.7% was seen at 36mos.
- Further analysis of resected tumors demonstrated anti-tumor response by altering the tumor microenvironment leading to cytotoxic lymphocyte activation and elevated proinflammatory cytokines
Ref: Candel Therapeutics | Image: Candel Therapeutics
Related News:- SN BioScience’s SNB-101 Gains Orphan Drug Designation from the US FDA for the Treatment of Pancreatic Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
